A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus | Zendy

James A. Hill | Zendy; Manfred Hummel | Zendy; Randall C. Starling | Zendy; Jon Kobashigawa | Zendy; Sergio V. Perrone | Zendy; José M. Arizón | Zendy; Svein Simonsen | Zendy; Kamal Abeywickrama | Zendy; Christoph Bara | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus

Author(s) -

James A. Hill,

Manfred Hummel,

Randall C. Starling,

Jon Kobashigawa,

Sergio V. Perrone,

José M. Arizón,

Svein Simonsen,

Kamal Abeywickrama,

Christoph Bara

Publication year - 2007

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/01.tp.0000290686.68910.bd

Subject(s) - everolimus , medicine , cytomegalovirus , incidence (geometry) , gastroenterology , regimen , heart transplantation , randomized controlled trial , azathioprine , transplantation , immunology , herpesviridae , disease , virus , viral disease , physics , optics

Cytomegalovirus (CMV) infection in recipients of cardiac transplants is associated with higher rates of morbidity. A recent phase III trial showed highly significantly (P<0.001) lower CMV rates with the proliferation signal inhibitor everolimus compared to azathioprine (AZA). To better define this association, data on CMV risk factors were collected retrospectively and analyzed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research